A375 NY−ESO−1 Antigen Panel Cell Lines

This product is a panel of three (3) genetically modified cell lines involving the NY-ESO-1 gene. The panel consists of a NY-ESO-1 knockout cell line (NY-ESO-1^-/-) as well as a NY-ESO-1^low and a NY-ESO-1^high expression cell line. The NY-ESO-1^-/- cell line was generated using CompoZr^® Zinc Finger Nuclease technology, and the two NY-ESO-1 expression cell lines were generated using MISSION^® lentivirus. The NY-ESO-1^low and NY-ESO-1^high cell lines express NY-ESO-1 at low and high levels relative to the NY-ESO-1^-/- cell line (NY-ESO-1^high > NY-ESO-1^low > NY-ESO-1^-/-) as measured via fluorescence-activated cell sorting (FACS). As a comparison, wild type A375 cells demonstrate NY-ESO-1^medium expression as measured via FACS.

The STR profile of these cell lines match that of its parental cell line - ECACC catalog number 88113005.

Derived from a 54 year old female with malignant melanoma. The cell line produces rapidly growing amelanotic melanomas in anti-thymocyte serum treated NIH Swiss mice.

The A375 NY-ESO-1 antigen panel cell lines feature NY-ESO-1 expressed at varying levels (KO, low, and high). These cell lines enable researchers to screen and evaluate the efficacy and potency of NY-ESO-1-targeted immunotherapies in a biologically-relevant cellular research model.

ATG004A-1VL: A375 NY-ESO-1 Knockout
ATG004B-1VL: A375 NY-ESO-1 Low
ATG004C-1VL: A375 NY-ESO-1 High

Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, and short terminal repeat (STR) analysis for cell line identification.

CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany